GADOLIN trial: In follicular lymphoma patients who were refractory to a rituximab-containing regimen

Overall survival: a post hoc analysis of GAZYVA + bendamustine followed by GAZYVA monotherapy vs bendamustine alone

With a median observation time of 24.1 months, GAZYVA + bendamustine followed by GAZYVA monotherapy reduced the risk of death by 38% vs bendamustine alone 1

GAZYVA GADOLIN Secondary Endpoint: Overall Survival Chart